Literature DB >> 12490962

Inflammation and therapeutic vaccination in CNS diseases.

Howard L Weiner1, Dennis J Selkoe.   

Abstract

The spectrum of inflammatory diseases of the central nervous system has been steadily expanding from classical autoimmune disorders such as multiple sclerosis to far more diverse diseases. Evidence now suggests that syndromes such as Alzheimer's disease and stroke have important inflammatory and immune components and may be amenable to treatment by anti-inflammatory and immunotherapeutic approaches. The notion of 'vaccinating' individuals against a neurodegenerative disorder such as Alzheimer's disease is a marked departure from classical thinking about mechanism and treatment, and yet therapeutic vaccines for both Alzheimer's disease and multiple sclerosis have been validated in animal models and are in the clinic. Such approaches, however, have the potential to induce unwanted inflammatory responses as well as to provide benefit.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490962     DOI: 10.1038/nature01325

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  68 in total

1.  Anti-inflammatory drugs and Alzheimer's disease.

Authors:  Christopher Martyn
Journal:  BMJ       Date:  2003-08-16

2.  On the catalytic activity of autoantibodies in multiple sclerosis.

Authors:  N A Ponomarenko; O M Durova; I I Vorob'ev; S V Suchkov; A G Gabibov
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

Review 3.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

Review 4.  Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.

Authors:  Maria Caramelli; Giuseppe Ru; Pierluigi Acutis; Gianluigi Forloni
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice.

Authors:  James H Park; Gabriel A Widi; David A Gimbel; Noam Y Harel; Daniel H S Lee; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2006-12-20       Impact factor: 6.167

6.  Pro- and anti-inflammatory cytokines regulate the ERK pathway: implication of the timing for the activation of microglial cells.

Authors:  K Saud; R Herrera-Molina; R Von Bernhardi
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

Review 7.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

Review 9.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

Review 10.  Immunotherapy for Alzheimer's disease.

Authors:  David S Gelinas; Kevin DaSilva; Daniela Fenili; Peter St George-Hyslop; Joanne McLaurin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.